Loading...

Provectus Biopharmaceuticals, Inc.

PVCT•PNK
Healthcare
Biotechnology
$0.06
$0.004(8.24%)
U.S. Market opens in 3h 4m

Provectus Biopharmaceuticals, Inc. (PVCT) Stock Overview

Explore Provectus Biopharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap22.1M
P/E Ratio-4.03
EPS (TTM)$-0.01
ROE0.93%
Fundamental Analysis

AI Price Forecasts

1 Month$0.04
3 Months$0.01
1 Year Target$0.01

PVCT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Provectus Biopharmaceuticals, Inc. (PVCT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 49.23, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.03 and a market capitalization of 22.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
8.24%
5-Day Change
2.60%
1-Month Change
13.20%
3-Month Change
2.60%
6-Month Change
-24.47%
Year-to-Date (YTD) Change
-1.25%
1-Year Change
-36.91%
3-Year Change
-61.64%
5-Year Change
-15.08%
All-Time (Max) Change
-100.00%

Contact Information

https://www.provectusbio.com
866 594 5999
10025 Investment Drive, Knoxville, TN, 37932

Company Facts

6 Employees
IPO DateJan 15, 1997
CountryUS
Actively Trading

Frequently Asked Questions